Certification: | ISO, FDA, HACCP |
---|---|
Assay Method: | HPLC |
Application Form: | Paste, Tablet, Capsule |
Application: | Food, Health Care Products |
State: | Powder |
Extract Source: | Mucuna Pruriens |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product Name: Levodopa
Specification:10.0%~ 90.0% Levodopa
Test Method: HPLC
Part of used: Seed
Appearance: Brown fine powder
PRODUCT SPECIFICATIONS | ||
Product Name: | Levodopa | |
Part of plant | Seed | |
Solvent extraction | 30% water & 70% ethanol | |
Country of Origin: | China | |
Excipent | 10% maltodextrin | |
ANALYSIS ITEMS | SPECIFICATION | TEST METHOD |
Appearance | Fine powder | Organoleptic |
Color | Brown | Visual |
Odour & Taste | Characteristic | Organoleptic |
Identification | Identical to R.S. sample | HPTLC |
Levodopa | 10.0%~90.0% | HPLC |
Solubility | Partly soluble in water | |
Hydrocarbons PAHs | ≤ 50 ppb -Reg.UE 1933/2015 | GC-MS |
Benzo(a)pyren | ≤ 10 ppb -Reg.UE 1933/2015 | GC-MS |
Radioactivity | ≤ 600 Bq/Kg -Reg. CE 1409/2009 | |
Apparent density | 0.4-0.7g/ml | |
Sieve Analysis | 100% through 80 mesh | USP39 <786> |
Loss on drying | ≤ 5.0% | Eur.Ph.9.0 [2.5.12] |
Total Ash | ≤ 5.0% | Eur.Ph.9.0 [2.4.16] |
Lead (Pb) | ≤ 3.0 mg/kg | Eur.Ph.9.0<2.2.58>ICP-MS |
Arsenic (As) | ≤ 1.0 mg/kg | Eur.Ph.9.0<2.2.58>ICP-MS |
Cadmium(Cd) | ≤ 1.0 mg/kg | Eur.Ph.9.0<2.2.58>ICP-MS |
Mercury(Hg) | ≤ 0.1 mg/kg -Reg.EC629/2008 | Eur.Ph.9.0<2.2.58>ICP-MS |
Heavy metal | ≤ 10.0 mg/kg | Eur.Ph.9.0 <2.4.8> |
Solvents Residue | Conform Eur.ph. 9.0 <5,4 > and EC European Directive 2009/32 | Eur.Ph.9.0<2.4.24> |
Pesticides Residues | Conform Regulations(EC) No.396/2005 including annexes and successive updates Reg.2008/839/CE | Gas Chromatography |
Aerobic bacteria(TAMC) | ≤1000 cfu/g | USP39 <61> |
Yeast/Moulds(TAMC) | ≤100 cfu/g | USP39 <61> |
Bile-tol.gram- b./Enterobact.: | ≤100 cfu/g | |
Escherichia coli: | Absent in 1g | USP39 <62> |
Salmonella spp: | Absent in 25g | USP39 <62> |
Staphylococcus aureus: | Absent in 1g | |
Listeria Monocytogenens | Absent in 25g | |
Aflatoxins B1 | ≤ 5 ppb -Reg.EC 1881/2006 | USP39 <62> |
Aflatoxins ∑ B1, B2, G1, G2 | ≤ 10 ppb -Reg.EC 1881/2006 | USP39 <62> |
Levodopa is currently one of the effective drugs in the treatment of paralysis tremors.
Levodopa has been shown to reduce the symptoms of Parkinson's disease.
Levodopa to treat hepatic coma and improve central function.
Levodopa increases bone density and reverses osteoporosis.
Levodopa promotes sleep and reduces fat.
Levodopa is currently one of the effective drugs in the treatment of paralysis tremors.
Suppliers with verified business licenses